Proteomic analyses identify HK1 and ATP5A to be overexpressed in distant metastases of lung adenocarcinomas compared to matched primary tumors

[1]  Kellen L. Olszewski,et al.  Spatial mapping of mitochondrial networks and bioenergetics in lung cancer , 2023, Nature.

[2]  Z. Szallasi,et al.  Proteomic analysis of brain metastatic lung adenocarcinoma reveals intertumoral heterogeneity and specific alterations associated with the timing of brain metastases , 2022, ESMO open.

[3]  S. Perner,et al.  Normics: Proteomic Normalization by Variance and Data-Inherent Correlation Structure , 2022, Molecular & cellular proteomics : MCP.

[4]  S. Perner,et al.  Systematic evaluation and optimization of protein extraction parameters in diagnostic FFPE specimens , 2022, Clinical Proteomics.

[5]  A. Schulz,et al.  Protein Expression of AEBP1, MCM4, and FABP4 Differentiate Osteogenic, Adipogenic, and Mesenchymal Stromal Stem Cells , 2022, International journal of molecular sciences.

[6]  M. Marz,et al.  A genome‐wide CRISPR activation screen reveals Hexokinase 1 as a critical factor in promoting resistance to multi‐kinase inhibitors in hepatocellular carcinoma cells , 2022, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  A. Brazma,et al.  The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences , 2021, Nucleic Acids Res..

[8]  E. Brzeziańska-Lasota,et al.  Proteomic biomarkers of non-small cell lung cancer patients. , 2021, Advances in respiratory medicine.

[9]  F. Klauschen,et al.  Comprehensive micro-scaled proteome and phosphoproteome characterization of archived retrospective cancer repositories , 2021, Nature Communications.

[10]  Dian Yang,et al.  Altered Mitochondria Functionality Defines a Metastatic Cell State in Lung Cancer and Creates an Exploitable Vulnerability , 2020, Cancer Research.

[11]  Paul D Piehowski,et al.  A review of imputation strategies for isobaric labeling-based shotgun proteomics. , 2020, Journal of proteome research.

[12]  I. Jonassen,et al.  Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression , 2020, Cell.

[13]  Junming Xu,et al.  Integrative Proteomic Characterization of Human Lung Adenocarcinoma , 2020, Cell.

[14]  Jeffrey R. Whiteaker,et al.  Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma , 2020, Cell.

[15]  W. Klepetko,et al.  Current therapy of KRAS-mutant lung cancer , 2020, Cancer and Metastasis Reviews.

[16]  H. Kwon,et al.  Proteomic analysis enables distinction of early‐ versus advanced‐stage lung adenocarcinomas , 2020, Clinical and translational medicine.

[17]  R. Gasparri,et al.  Clinical Application of Mass Spectrometry‐Based Proteomics in Lung Cancer Early Diagnosis , 2020, Proteomics. Clinical applications.

[18]  J. Nikliński,et al.  Identification of protein changes in the blood plasma of lung cancer patients subjected to chemotherapy using a 2D-DIGE approach , 2019, PloS one.

[19]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[20]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[21]  Gautam Sethi,et al.  Sorcin a Potential Molecular Target for Cancer Therapy , 2018, Translational oncology.

[22]  T. Graeber,et al.  A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers , 2018, Cancer & Metabolism.

[23]  P. Maher,et al.  The mitochondrial ATP synthase is a shared drug target for aging and dementia , 2018, Aging cell.

[24]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.

[25]  Semon Wu,et al.  Haptoglobin is a serological biomarker for adenocarcinoma lung cancer by using the ProteomeLab PF2D combined with mass spectrometry. , 2016, American journal of cancer research.

[26]  Yu-Sun Chang,et al.  Identification and Characterization of Potential Biomarkers by Quantitative Tissue Proteomics of Primary Lung Adenocarcinoma* , 2016, Molecular & Cellular Proteomics.

[27]  Richard D. Smith,et al.  The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification , 2016, Expert review of proteomics.

[28]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[29]  Yan Li,et al.  Aberrant Mucin5B expression in lung adenocarcinomas detected by iTRAQ labeling quantitative proteomics and immunohistochemistry , 2013, Clinical Proteomics.

[30]  Abhishek K. Jha,et al.  Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. , 2013, Cancer cell.

[31]  T. Berkelman,et al.  A Defined Methodology for Reliable Quantification of Western Blot Data , 2013, Molecular Biotechnology.

[32]  K. J. Thomas,et al.  The role of mitochondria in the development and progression of lung cancer , 2013, Computational and structural biotechnology journal.

[33]  Francesca Pentimalli,et al.  Mass spectrometry-based proteomics: the road to lung cancer biomarker discovery. , 2013, Mass spectrometry reviews.

[34]  H. Juan,et al.  Ectopic ATP synthase blockade suppresses lung adenocarcinoma growth by activating the unfolded protein response. , 2012, Cancer research.

[35]  Sébastien Couraud,et al.  Lung cancer in never smokers--a review. , 2012, European journal of cancer.

[36]  Jiao-Yang Li,et al.  Identification of Candidate Biomarkers for Early Detection of Human Lung Squamous Cell Cancer by Quantitative Proteomics* , 2012, Molecular & Cellular Proteomics.

[37]  Yie Yang,et al.  Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer , 2010, Medical oncology.

[38]  P. He,et al.  Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis. , 2010, Oncology reports.

[39]  M. P. Cadena,et al.  On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. , 2010, Journal of proteomics.

[40]  H. Tojo,et al.  Proteomic analysis of laser-microdissected paraffin-embedded tissues: (1) Stage-related protein candidates upon non-metastatic lung adenocarcinoma. , 2010, Journal of proteomics.

[41]  H. Tojo,et al.  Proteomic analysis of laser-microdissected paraffin-embedded tissues: (2) MRM assay for stage-related proteins upon non-metastatic lung adenocarcinoma. , 2010, Journal of proteomics.

[42]  M. Roehrl,et al.  Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma. , 2009, Journal of proteome research.

[43]  L. Gaspar,et al.  National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. , 2007, Lung cancer.

[44]  Haesun Park,et al.  Sparse non-negative matrix factorizations via alternating non-negativity-constrained least squares for microarray data analysis , 2007, Bioinform..

[45]  Ning Liu,et al.  Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis. , 2006, Biochemical and biophysical research communications.

[46]  Hoguen Kim,et al.  Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma , 2004, Proteomics.

[47]  C. Moskaluk,et al.  RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. , 2002, Cancer research.

[48]  B. Silvestrini,et al.  Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. , 1981, Cancer research.

[49]  Cathy H. Wu,et al.  UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..